# ğŸ§¬ In vivo CAR-T æ–‡çŒ®æœˆæŠ¥

> ğŸ“… æ›´æ–°æ—¥æœŸ: 2026-01-11 | â±ï¸ ç»Ÿè®¡èŒƒå›´: è¿‡å» 30 å¤© | ğŸ” å…³é”®è¯: In vivo CAR-T

## ğŸ“˜ æœ€æ–°ç»¼è¿° (Reviews) - å…± 6 ç¯‡
---
### [Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.](https://pubmed.ncbi.nlm.nih.gov/41513408/)
- ğŸ“š **æœŸåˆŠ**: *Journal for immunotherapy of cancer* | ğŸ“ˆ **IF: 10.9**
- **æ‘˜è¦**: Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors, including tumo...

### [Advancing Cancer Immunotherapy: Chimeric Antigen Receptor (CAR)-T Cell Engineering through Novel Screening Methods.](https://pubmed.ncbi.nlm.nih.gov/41490986/)
- ğŸ“š **æœŸåˆŠ**: *Biomolecules & therapeutics* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Cancer immunotherapy represents a paradigm-shifting achievement in oncology. Particularly, chimeric antigen receptor (CAR)-T cell therapy utilizing genetically engineered T cells has produced remarkab...

### [Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Based Therapies.](https://pubmed.ncbi.nlm.nih.gov/41440494/)
- ğŸ“š **æœŸåˆŠ**: *Antibodies (Basel, Switzerland)* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor (CAR)-based immunotherapy has emerged as a transformative strategy in anticancer treatment, driven by advances in CAR construct design, manufacturing platforms, and expansion...

### [Targeting immune heterogeneity in liver metastases through in vivo genetic engineering.](https://pubmed.ncbi.nlm.nih.gov/41401477/)
- ğŸ“š **æœŸåˆŠ**: *Seminars in immunology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: The liver is both a central metabolic organ and a uniquely tolerogenic immune niche, which makes it a frequent site of liver metastases (LMS) and a challenging environment for immunotherapy. It is inc...

### [Current landscape of CAR-therapy for osteosarcoma and rhabdomyosarcoma.](https://pubmed.ncbi.nlm.nih.gov/41394804/)
- ğŸ“š **æœŸåˆŠ**: *Frontiers in immunology* | ğŸ“ˆ **IF: 7.3**
- **æ‘˜è¦**: Osteosarcoma (OS) and rhabdomyosarcoma (RMS) are the most prevalent pediatric sarcoma subtypes of the bones and soft tissues respectively. The lack in targeted treatment approaches alongside the gener...

### [CAR T-cell therapy for neurological disorders: scientific rationale and mechanistic insights.](https://pubmed.ncbi.nlm.nih.gov/41394288/)
- ğŸ“š **æœŸåˆŠ**: *Therapeutic advances in neurological disorders* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: The development and successful clinical application of engineered T cells expressing synthetic chimeric antigen receptors (CARs) represents a milestone in cancer therapy. This approach optimizes physi...

## ğŸ”¬ æœ€æ–°ç ”ç©¶è®ºæ–‡ (Articles) - å…± 39 ç¯‡
---
### [Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations.](https://pubmed.ncbi.nlm.nih.gov/41513407/)
- ğŸ“š **æœŸåˆŠ**: *Journal for immunotherapy of cancer* | ğŸ“ˆ **IF: 10.9**
- **æ‘˜è¦**: Engineering chimeric antigen receptor (CAR) T cells with logic-gated synthetic Notch (synNotch) receptor circuits can enhance specificity and mitigate on-target/off-tumor toxicity. However, the conven...

### [PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters.](https://pubmed.ncbi.nlm.nih.gov/41507351/)
- ğŸ“š **æœŸåˆŠ**: *Communications biology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: The combination of chimeric antigen receptor (CAR)-T cell therapy with immune checkpoint blockade (ICB) using anti-PD-1 has been demonstrated to enhance antitumor CAR-T cell responses. Although, in co...

### [HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling.](https://pubmed.ncbi.nlm.nih.gov/41501787/)
- ğŸ“š **æœŸåˆŠ**: *Cell communication and signaling : CCS* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor (CAR) T cell therapy has shown success in hematological malignancies, but its efficacy against solid tumors remains limited. Herpesvirus entry mediator (HVEM), a co-stimulato...

### [Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.](https://pubmed.ncbi.nlm.nih.gov/41501251/)
- ğŸ“š **æœŸåˆŠ**: *Nature biomedical engineering* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Major challenges facing chimeric antigen receptor (CAR)-T cell therapy for solid tumours include the immunosuppressive tumour microenvironment and the heterogeneity of antigen expression. Bacterial ou...

### [Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors.](https://pubmed.ncbi.nlm.nih.gov/41500474/)
- ğŸ“š **æœŸåˆŠ**: *Biochemical pharmacology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: In current clinical applications, there are challenges with using chimeric antigen receptor (CAR)-T cells to effectively treat solid tumors. These challenges include promoting the infiltration and pro...

### [The LXRÎ²/NF-ÎºB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment.](https://pubmed.ncbi.nlm.nih.gov/41496523/)
- ğŸ“š **æœŸåˆŠ**: *Oncoimmunology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Liver X receptor Î² (LXRÎ²) is a key transcription factor involved in lipid metabolism and immune regulation, yet its functional role in tumor-infiltrating T cells remains largely unresolved. While LXRÎ²...

### [In Vivo Generation and Manipulation of CAR-T-mimicking Cells via Magnetic Bispecific Nano-antibody for Solid Tumor Therapy.](https://pubmed.ncbi.nlm.nih.gov/41495981/)
- ğŸ“š **æœŸåˆŠ**: *Advanced materials (Deerfield Beach, Fla.)* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: The therapeutic efficacy of chimeric antigen receptor (CAR)-T cell therapy in combating solid tumors remains constrained, primarily due to inadequate tumor infiltration and the immunosuppressive tumor...

### [CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency.](https://pubmed.ncbi.nlm.nih.gov/41495526/)
- ğŸ“š **æœŸåˆŠ**: *Nature cancer* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Insufficient functional T cell persistence impedes therapeutic success of chimeric antigen receptor (CAR) therapies. Here we performed a CAR-adapted base-editing screen of PIK3CD, a key regulator of T...

### [Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy.](https://pubmed.ncbi.nlm.nih.gov/41490421/)
- ğŸ“š **æœŸåˆŠ**: *Cancer research* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor (CAR)-T cell therapy enables potent, antigen-specific immune responses and has demonstrated success in treating hematologic malignancies. However, conventional ex vivo CAR-T ...

### [Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.](https://pubmed.ncbi.nlm.nih.gov/41490267/)
- ğŸ“š **æœŸåˆŠ**: *Blood* | ğŸ“ˆ **IF: 20.3**
- **æ‘˜è¦**: Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. Development of chime...

### [BASIC Enables Selection-Free Efficient Knock-In of Large DNA in Primary Human T Cells.](https://pubmed.ncbi.nlm.nih.gov/41485050/)
- ğŸ“š **æœŸåˆŠ**: *Molecular therapy : the journal of the American Society of Gene Therapy* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Efficient and precise insertion of large DNA fragments into primary human T cells has remained a bottleneck for gene and cell therapy. We present BASIC, a modular platform that combines BaEVshort-pseu...

### [CD96 as a Therapeutic Target for CAR T-Cell Therapy in Acute Myeloid Leukemia.](https://pubmed.ncbi.nlm.nih.gov/41485047/)
- ğŸ“š **æœŸåˆŠ**: *Molecular therapy : the journal of the American Society of Gene Therapy* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Therapies leveraging chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) are limited by the scarcity of leukemia stem cell (LSC)-specific antigens. Here, we found that CD96 is exp...

### [Disulfide-Directed Multicyclic Peptides for Chimeric Antigen Receptors Targeting Solid Tumors.](https://pubmed.ncbi.nlm.nih.gov/41480930/)
- ğŸ“š **æœŸåˆŠ**: *Journal of the American Chemical Society* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: The clinical application of chimeric antigen receptor (CAR) T cell therapy in solid tumors remains limited due to significant safety concerns, particularly "on-target, off-tumor" toxicity and cytokine...

### [Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13RÎ±2 CAR-T Cells InÂ Vivo.](https://pubmed.ncbi.nlm.nih.gov/41469157/)
- ğŸ“š **æœŸåˆŠ**: *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor (CAR)-T cell therapy has shown limited success in the treatment of solid tumors, reinforcing the need to elucidate the inÂ vivo biodistribution of these engineered T cells. He...

### [Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.](https://pubmed.ncbi.nlm.nih.gov/41469141/)
- ğŸ“š **æœŸåˆŠ**: *Journal for immunotherapy of cancer* | ğŸ“ˆ **IF: 10.9**
- **æ‘˜è¦**: Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen density on tu...

### [Antigen-Specific Chimeric Antigen Receptor-T Regulatory Cells Home to Human Islets, Suppress Cytotoxic T Lymphocytes and Reverse Type 1 Diabetes.](https://pubmed.ncbi.nlm.nih.gov/41468096/)
- ğŸ“š **æœŸåˆŠ**: *Diabetes technology & therapeutics* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: <b><i>Background:</i></b> We have developed pancreatic beta-cell, antigen-specific, chimeric antigen receptor (CAR) T regulatory cells (Tregs) and explored their therapeutic potential for type 1 diabe...

### [Expression of the CXCR4 S338X Variant Improves Anti-Leukemia Efficacy of Anti-CD19 CAR-T Cells.](https://pubmed.ncbi.nlm.nih.gov/41467552/)
- ğŸ“š **æœŸåˆŠ**: *Cancer science* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable success in treating hematological malignancies; however, antigen-positive relapse remains a significant obstacle to achievi...

### [Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone Disease.](https://pubmed.ncbi.nlm.nih.gov/41463400/)
- ğŸ“š **æœŸåˆŠ**: *Biomolecules* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Multiple myeloma (MM) is a plasma cell malignancy that disrupts bone homeostasis by suppressing osteogenesis and promoting osteoclast activity. While most therapeutic interventions to date have focuse...

### [2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity.](https://pubmed.ncbi.nlm.nih.gov/41459521/)
- ğŸ“š **æœŸåˆŠ**: *Frontiers in immunology* | ğŸ“ˆ **IF: 7.3**
- **æ‘˜è¦**: Chimeric Antigen Receptor (CAR)-based therapies have transformed cancer treatment, especially in hematological malignancies. While the impact of co-stimulatory domains on CAR-T cell efficacy is well e...

### [Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR.](https://pubmed.ncbi.nlm.nih.gov/41449802/)
- ğŸ“š **æœŸåˆŠ**: *Molecular therapy : the journal of the American Society of Gene Therapy* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor (CAR) T cells targeting CD19 are highly effective against B lineage malignancies. However, about half of patients either fail to achieve complete remission (in the case of ly...

### [Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy.](https://pubmed.ncbi.nlm.nih.gov/41446213/)
- ğŸ“š **æœŸåˆŠ**: *bioRxiv : the preprint server for biology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: T cell exhaustion limits the efficacy of cancer immunotherapies. Here, we performed genome-wide loss-of-function screening in repetitively stimulated human T cells and identified the mulitfunctional u...

### [Cre-dependent gene expression enables thymic development of autoreactive tumor-associated antigen targeting CAR-T cells.](https://pubmed.ncbi.nlm.nih.gov/41445186/)
- ğŸ“š **æœŸåˆŠ**: *Molecular therapy : the journal of the American Society of Gene Therapy* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor (CAR)-T cells have revolutionized cancer therapy by enabling highly specific adoptive cellular treatments. However, limited in vivo persistence and tumor relapse remain major...

### [Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma.](https://pubmed.ncbi.nlm.nih.gov/41439964/)
- ğŸ“š **æœŸåˆŠ**: *Cells* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Multiple myeloma (MM) is an incurable hematologic malignancy arising from clonal plasma cells, with poor long-term outcomes due to inevitable relapse after conventional therapies. Chimeric antigen rec...

### [Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy.](https://pubmed.ncbi.nlm.nih.gov/41430032/)
- ğŸ“š **æœŸåˆŠ**: *Signal transduction and targeted therapy* | ğŸ“ˆ **IF: 39.3**
- **æ‘˜è¦**: Messenger RNA (mRNA)-based transient expression of chimeric antigen receptors (CARs) results in optimal safety profiles and provides promising opportunities to address existing challenges associated w...

### [2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.](https://pubmed.ncbi.nlm.nih.gov/41428622/)
- ğŸ“š **æœŸåˆŠ**: *Turkish journal of haematology : official journal of Turkish Society of Haematology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Despite PFS in MM patients extending to 17 years due to contemporary quadruplet induction therapies, there remains a necessity for novel products in the treatment of high-risk patients. BCMA, GPRC5D, ...

### [Sequential pseudoallogeneic CAR20/22/19 T-cell therapy in patient with diffuse large B-cell lymphoma relapse after allo-HSCT: a case report.](https://pubmed.ncbi.nlm.nih.gov/41425542/)
- ğŸ“š **æœŸåˆŠ**: *Frontiers in immunology* | ğŸ“ˆ **IF: 7.3**
- **æ‘˜è¦**: The prognosis for patients with refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) is dismal. Recurrence in R/R DLBCL is mostly determined by antigen loss or mutation and the limited <i>in ...

### [CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer.](https://pubmed.ncbi.nlm.nih.gov/41424784/)
- ğŸ“š **æœŸåˆŠ**: *Frontiers in pharmacology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Solid tumors present a significant challenge to Chimeric Antigen Receptor (CAR) -T cell therapy, primarily due to limited T-cell infiltration and persistence in the tumor microenvironment. Cancers wit...

### [AMPK agonism optimizes the in vivo activation and antileukemic efficacy of chimeric antigen receptor T cells.](https://pubmed.ncbi.nlm.nih.gov/41423271/)
- ğŸ“š **æœŸåˆŠ**: *Journal for immunotherapy of cancer* | ğŸ“ˆ **IF: 10.9**
- **æ‘˜è¦**: Chimeric antigen receptor (CAR) T cells have achieved remarkable clinical success. However, up to 50% of patients with CAR T-cell treated leukemia relapse and long-term survivor data indicate that CAR...

### [Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy.](https://pubmed.ncbi.nlm.nih.gov/41419632/)
- ğŸ“š **æœŸåˆŠ**: *Cell death & disease* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has achieved notable efficacy in relapsed/refractory multiple myeloma (RRMM), yet most patients eventually r...

### [Preclinical evaluation of CAR-T cell immunotherapy with a fully human EpCAM-specific scFv against pancreatic cancer.](https://pubmed.ncbi.nlm.nih.gov/41417221/)
- ğŸ“š **æœŸåˆŠ**: *Cancer immunology, immunotherapy : CII* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Pancreatic cancer is an aggressive malignancy with poor prognosis. Recent advances in chimeric antigen receptor (CAR)-T cell immunotherapy have offered renewed hope. The pivotal factors determining th...

### [Vitamin C conditioning generates tumor-targeting CAR T cells with superior cytotoxicity and fitness in a post-transplant lymphoproliferative disorder tumor model.](https://pubmed.ncbi.nlm.nih.gov/41416402/)
- ğŸ“š **æœŸåˆŠ**: *Molecular cancer therapeutics* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: CAR T-cell therapy has shown efficacy in hematological malignancies but faces challenges in solid tumors and virus-associated malignancies such as post-transplant lymphoproliferative disorder (PTLD). ...

### [Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.](https://pubmed.ncbi.nlm.nih.gov/41410870/)
- ğŸ“š **æœŸåˆŠ**: *Cancer immunology, immunotherapy : CII* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion. Pomalidomide, ...

### [Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.](https://pubmed.ncbi.nlm.nih.gov/41408462/)
- ğŸ“š **æœŸåˆŠ**: *Oncogene* | ğŸ“ˆ **IF: 8.0**
- **æ‘˜è¦**: Ovarian cancer (OC) remains a lethal malignancy with limited treatment options owing to antigen heterogeneity and an immunosuppressive tumor microenvironment (TME). Here, we designed a unique chimeric...

### [In Vivo CAR T Cells Deliver Deep Responses in Myeloma.](https://pubmed.ncbi.nlm.nih.gov/41405215/)
- ğŸ“š **æœŸåˆŠ**: *Cancer discovery* | ğŸ“ˆ **IF: 28.2**
- **æ‘˜è¦**: Early clinical results show that inside-the-body T-cell engineering can trigger rapid chimeric antigen receptor expression and induce deep responses in patients with relapsed multiple myeloma-without ...

### [Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential.](https://pubmed.ncbi.nlm.nih.gov/41404500/)
- ğŸ“š **æœŸåˆŠ**: *Molecular therapy. Nucleic acids* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Several allogeneic chimeric antigen receptor (CAR) T-cell therapies in clinical trials rely on CRISPR-Cas genome editing, but the enzyme's random repair mechanism increases the risk of undesired off-t...

### [Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells.](https://pubmed.ncbi.nlm.nih.gov/41397639/)
- ğŸ“š **æœŸåˆŠ**: *Biochemical pharmacology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Mesothelin (MSLN), overexpressed in >90Â % of malignant pleural mesotheliomas and pancreatic adenocarcinomas, with minimal expression in normal tissue, represents an ideal immunotherapeutic target. Her...

### [CD155-based chimeric antigen receptor T cells: a promising immunotherapy for cervical and breast cancer.](https://pubmed.ncbi.nlm.nih.gov/41394877/)
- ğŸ“š **æœŸåˆŠ**: *Frontiers in immunology* | ğŸ“ˆ **IF: 7.3**
- **æ‘˜è¦**: As an immune checkpoint molecule that is overexpressed in cervical and breast cancer, CD155 represents an attractive target for chimeric antigen receptor (CAR) T-cell therapy. However, it is crucial t...

### [Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editing.](https://pubmed.ncbi.nlm.nih.gov/41394272/)
- ğŸ“š **æœŸåˆŠ**: *Molecular therapy. Oncology* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: The disruption of immune checkpoints in T cells is a promising tool for improving the efficacy of tumor-infiltrating lymphocyte (TIL) therapy. While CRISPR-Cas9 genome-editing is efficient, Cas9 nucle...

### [Fucoidan potentiates anti-tumor efficacy of CAR-T cells against non-Hodgkin lymphoma by activation of STAT3 pathway.](https://pubmed.ncbi.nlm.nih.gov/41390428/)
- ğŸ“š **æœŸåˆŠ**: *Journal of translational medicine* | ğŸ“ˆ IF: N/A
- **æ‘˜è¦**: Despite advances in chimeric antigen receptor T-cell (CAR-T) therapy, significant challenges remain, including progressive T-cell exhaustion and poor in vivo persistence. Current strategies to enhance...

